Press Release - ITG Isotope Technologies Garching GmbH (ITG) - specialist in innovative radioisotopes - expands its nuclear reactor and technology network in line with its strategy to guarantee global security of supply.

In May 2012, ITG - a fully-owned subsidiary of ITM Isotopen Technologien München AG (ITM) based in Germany - and NTP Radioisotopes SOC Ltd (NTP) - a subsidiary of the South African Nuclear Energy Corporation (NECSA) - agreed on a substantial collaboration regarding radioisotopes. The cooperation is an important milestone in ensuring a reliable supply of high quality radioisotopes for Africa and Brazil. As a first step, NTP and ITG have agreed on a technology transfer for the unique isotope ITG Lu-177 n.c.a. (non carrier added). In addition, ITG will expand its already well-established global reactor network by cooperating with NECSA’s Safari-1 nuclear reactor.

Lutetium-177 plays a key role in nuclear medicine in the treatment of neuroendocrine tumors, and has displayed strong growth potential. In comparison to other production routes, every atom of the ITG Lu-177 n.c.a. is radioactive. This results in specific activity many times higher than similar products, therefore rendering treatments more effective. The contamination with the long lived isomer Lu-177m is negligible. NTP has in-licensed the production technology and will hence be the exclusive distribution partner for ITG products in Africa.

Safari-1 nuclear reactor is one of only five reactors in the world, which together produce 98% of the world’s radionuclides for the medical sector. Steffen Schuster, CEO of ITM states: "In the recent past, SAFARI-1 has been instrumental in securing the supply of radiopharmaceuticals (via NTP) into the world market when reactors were down due to unforeseen problems. It sends a strong signal to those companies working with Lu-177-based therapies - global supply is guaranteed and the agreement serves as proof of the value of our production expertise.".

ITG is a well-established company in the supply of next generation isotopes and technology. The company provides highly effective radioisotopes, such as the ITG Lu-177 n.c.a., the ITG Ge-68/Ga-68 Generator and the ITG W-188/Re-188 Generator, as well as corresponding customized devices. ITG is renowned for its dedicated team providing outstanding reliability in both quality and supply. ITG has an esteemed global network of sales partners and strategic cooperations.

NTP is recognized as a leading global supplier of radioisotopes. NTP manufactures a range of radioisotope products for use in downstream medical devices and procedures as well as in industry. They have maintained consistent growth in over 60 countries and in customers served.

Germany, München/ Garching, June 08, 2012

The alliance of ITG and NTP will further enhance their international competitiveness as well as reinforce their prominent position as a reliable and attractive partner for their customers worldwide.

For further information please contact:

ITG Isotope Technologies Garching GmbH

Dr. Richard Henkelmann, Managing Director

+49 89 289-13946

This e-mail address is being protected from spambots. You need JavaScript enabled to view it

For media and investor enquiries please contact:

ITM Isotopen Technologien München AG

Steffen Schuster, CEO

+49 89 289-13970

This e-mail address is being protected from spambots. You need JavaScript enabled to view it

As of December 2011, ITG Isotope Technologies Garching GmbH has successfully passed the audit of the GMP production of the Lu-177 n.c.a. and has subsequently received the “Herstellungserlaubnis”. More than 15 reactors and accelerators in Europe, Australia, Africa, Russia and the FRM II form a network of irradiation facilities for ITG´s radioisotopes.

For further inquiries or if you would like to schedule a meeting with our representatives please contact: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Garching, Germany, June 3, 2011. ITG Isotope Technologies Garching GmbH (ITG), a specialist in the development and production of innovative radioisotopes, and Sydney-based, Australian Nuclear Science and Technology Organisation (ANSTO) have agreed on a broad, long-term collaboration on radioisotopes.

ANSTO has in-licensed the production technology for ITG´s carrier free Lutetium-177 (Lu-177 n.c.a.) and will be the exclusive distribution partner for ITG´s products in Australia & New Zealand.

Both partners have agreed to provide each other with a backup supply of the radioisotope when needed as well as forming a collaboration for the supply of Lu-177 n.c.a. to industrial partners in the life science industry. Financial terms were not disclosed.

Dr. Richard Henkelmann and Dr. Andreas Hey, Managing Directors of ITG, stated “This agreement is a significant milestone in the corporate development of our company and serves as proof of the value of our production technology for Lu-177 n.c.a. It sends a strong signal to those companies developing Lutetium-177-based radiotherapies that global supply is guaranteed. Furthermore, adding ANSTO to our existing network of world-wide distribution partners closes an important geographical gap“.

Mr Doug Cubbin, Head of ANSTO’s Business Development and Commercialisation said “This is a great opportunity for ANSTO and the Asia Pacific region as it will accelerate the availability of locally produced Lu-177 within the region and the collaboration between ANSTO and ITG will underpin the future supply of an important radioisotope“.

About ITG: ITG Isotope Technologies Garching GmbH, a subsidiary of ITM Isotopen Technologien München AG (www.itm.ag), develops, manufactures and distributes world-wide innovative radio-isotopes for use in diagnosis and therapy.

About ANSTO: The Australian Nuclear Science and Technology Organisation produces radioisotopes, isotopic techniques and nuclear radiation for medicine, science, industry, commerce and agriculture as one of its core functions. For more please visit: www.ansto.gov.au

Your contact partner for any enquiries:

ITG Isotope Technologies Garching GmbH, Dr. Andreas Hey, Lichtenbergstr. 1, 85748 Garching,   Phone: +49 89 289-13913, This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Download

Ascenion has mediated a license agreement between the Helmholtz Zentrum München and ITM Isotopen Technologien München AG providing the company with exclusive rights to monoclonal antibodies targeting mutant forms of E-cadherin. These forms, D8- and D9-cadherin, are only present on certain gastric cancer cells, but not on healthy tissues. ITM, a leading developer of radioisotope therapies and integrated application systems, plans to conjugate the antibodies to certain radioisotopes (Alpha- and Betaemitting) and develop them for specific gastric cancer treatment. The Helmholtz Zentrum München receives license fees and is eligible to royalties on potential sales.


For further information please contact: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

The Technical University of Munich’s Central Institute for Medical Technologies (IMETUM) and the ITM Group have initiated a collaborative scientific program “BetaTop” with the objective to study and explore the therapeutic effects and healing mechanism of Beta Radiation (i.e. Rhenium-188) in the treatment of Skin Cancer and Re-Stenosis Therapy in endovascular treatments.

The Program is intended to address the macroscopic, microscopic and cellular aspects of Beta-Emitter and Topical Therapies and will be performed in collaboration with a group of leading medical and scientific institutions involved in the development of Epidermal Radioisotope Therapy and Endovascular Therapy.

Dr. Tuomo Nikula, Director of Technology Development of the ITM Group, has been appointed as Program Manager for the "BetaTop" program.

For further information please contact: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

The 4th International Conference on Radiopharmaceutical Therapy in conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)  will continue to be an important international forum for sharing the knowledge and professional expertise.

For further inquiries or if you would like to schedule a meeting with our representatives please contact: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

ITG Isotope Technologies Garching GmbH is presenting a new generation of highly effective radioisotopes (Lu-177 n.c.a., Ga-68, Re-188, Bi-213), generators and labeling systems at or booth. Also find out more about the advantages of the ITM Rhenium-PTA® for the effective treatment of Re-Stenosis in pAOD and the ITM Rhenium-SCT, the New Generation of Non-Invasive Skin Cancer Therapy.

Please visit us at booth 4 at the National Indoor Arena - NIA, (near the Main Entrance) or schedule a meeting with us. We are looking forward to seeing You.

For further Information please contact: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

We are looking forward to meeting you at the “TUM Forschung Live - Tag der offenen Tür”, October 15th 2011 from 11am to 6pm, in Garching (near Munich) – Technische Universität München (TUM). Please visit us at our booth located in the foyer of the department of Physics. We will present our cutting-edge innovations for personalized medicine especially in cancer research and cancer therapy.

For further information on the “Forschung Live - Tag der offenen Tür”, visit http://www.forschung-garching.de

or contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it

The International Conference on Isotopes - ICI7 - will continue to be an important international forum for sharing the knowledge and professional expertise in isotope applications for the benefit of all human beings.

For further inquiries or if you would like to schedule a meeting with our representatives please contact: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

We are looking forward to meeting you at our booth at the 1st World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy in Bad Berka, Germany from 23rd-26th of June 2011.

Join the presentation at the Pre-Congress Symposium

23rd of June 2011 at 2.40 p.m.
Dr. Jernström - “ITG iQS® Ga-68 Fluidic Labeling Module”

23rd of June 2011 at 3.50 p.m.
Dr. Harfensteller - "Challenges in Production of Therapeutic Isotopes"

Poster Viewing

24th of June 2011
Dr. Jernström - “Ge-68/Ga-68 Labeling System for Efficient and Cost Effective Labeling of Radiopharmaceuticals”
Dr. Harfensteller - “Radiometals for Therapeutic Application: Availability and Future Prospects”

For further Information please contact: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

The SNM Annual Meeting has been recognized as the premier educational and networking event in molecular imaging and nuclear medicine in the United
States of America.

For further inquiries or if you woud like to schedule a meeting with our representatives please contact: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

We are looking forward to meeting you at the 44th Annual Scientific Meeting of the Australasian College of Dermatologists "ACD" in the Riverside Theatre of the Perth Convention and Exhibition Centre (PCEC) in Western Australia from 15th to 18th of May 2011.

One Highlight of this event is the skin cancer symposium on May 16th, 2011.

Oliver Buck (CEO ITM AG and member of the Board of ITM OncoBeta GmbH) will give a talk about topical radiotherapy using Rhenium-188 (Rhenium-SCT) for SCC/BCC in the session from 1.30 pm to 3.00 pm.

We are looking forward to meeting you at the ACD Meeting

For further information please visit the website of the 44th Annual Scientific Meeting of the Australasian College of Dermatologists "ACD" or contact OncoBeta Australia Pty. Ltd., Dr. Michael Hauck (Managing Director).

Meet us at "NuklearMedizin 2011", the 3^rd International Congress of the German, Austrian and Swiss Associations of Nuclear Medicine at the Festspielhaus in Bregenz, Austria from 13^th to 16^th of April, 2011.

ITM AG, ITG Isotope Technologies Garching GmbH and ITM OncoBeta GmbH will present the latest advances in Radioisotope Products and -applications in medicine.

We are looking forward to meeting you at our booth No. F18, Foyer 2.

For further information please visit the website "NuklearMedizin 2011.

We are looking forward to meeting you at our booth no. 70 at the International Congress “Forum Life Science 2011”, March 23^rd to 24^th 2011, in Garching (near Munich) – Technische Universität München (TUM).

Highlight of this event will be an exclusive visit to the Neutron Source FRM II and the ITM Isotopen Technologien München AG at the Conference:

Tuesday, 22^nd of March 2011, 3:00 p.m. – 5:00 p.m.

Friday, 25^th of March 2011, 10:00 a.m. – 12:00 p.m.

Please register for one of the dates via email to This e-mail address is being protected from spambots. You need JavaScript enabled to view it until 16^th of March 2011.

For further information on the International Congress “Forum Life Science 2011” organized by the Bayern Innovative Ltd., an internationally renowned centre for knowledge and technology transfer, please visit "Forum Life Science 2011".

Mr. Benedikt Stöckert, who has managed the itm Rhenium SCT development program since 2009 has been appointed managing director (Geschäftsführer) of itm OncoBeta GmbH, effective February 15th, 2011.

At the same time, Mr Oliver Buck, CEO of OncoBetas parent company ITM AG and OncoBetas founding managing director has joined the board (Beirat) of ITM OncoBeta GmbH.

For further Information please contact: This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

In August 2010 ITM OncoBeta GmbH has formed a wholly owned daughter company “Oncobeta Australia PTY, Ltd” with headquarters in Perth, Westaustralia.

OncoBeta Australia is headed by Dr. Michael Hauck and will be responsible for all business development, regulatory affairs and customer relations in conjunction with the introduction of the ITM Rhenium-SCT in Australia. Australia is the region in the world with the highest incidence of skin cancer per capita.